Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20337209 | 1.00 | TYMP (0.43) | TYMPADORA2AADORA2BP2RY12P2RY2 | |
| SCHEMBL20348406 | 0.97 | TYMP (0.41) | TYMPADORA2AADORA2BP2RY12P2RY2 | |
| SCHEMBL20337206 | 0.95 | TYMP (0.43) | TYMPADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL20353027 | 0.95 | TYMP (0.43) | TYMPADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL20348400 | 0.92 | TYMP (0.41) | TYMPADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL17325411 | 0.90 | TYMP (0.46) | TYMPADORA2AADORA2B | |
| SCHEMBL20337102 | 0.87 | TYMP (0.41) | TYMPADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL20348403 | 0.87 | TYMP (0.44) | TYMPADORA2AADORA2B | |
| SCHEMBL28633882 | 0.86 | TYMP (0.44) | TYMPADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL28635435 | 0.86 | TYMP (0.44) | TYMPADORA2AADORA2BP2RY12ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450341-B2 | Cyclic di-nucleotides as modulators of STING | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| EP-3152217-B1 | CYCLIC DI-NUCLEOTIDES AS MODULATORS OF STING | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-08-01 | — | — | EP | disclosed |
| US-20180186828-A1 | CYCLIC DI-NUCLEOTIDES AS MODULATORS OF STING | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450341-B2 | Cyclic di-nucleotides as modulators of STING | STING1, CGAS, IRF3 | TYMP 423/4885ADORA2A 376/4885ADORA2B 320/4885 |
| US-20180186828-A1 | CYCLIC DI-NUCLEOTIDES AS MODULATORS OF STING | STING1, CGAS, IRF3 | TYMP 423/4885ADORA2A 376/4885ADORA2B 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.